Greater Cannabis Company (GCAN) Cost of Revenue (2017 - 2026)

Greater Cannabis Company's Cost of Revenue history runs 10 years deep, the most recent figure standing at $3376.0 for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 70.17% year-over-year to $3376.0 in Q1 2026; TTM through Mar 2026 was $52845.0, a 51.44% increase from a year earlier, with the FY2025 full-year figure at $60788.0, up 94.36% from the prior year.
• Cost of Revenue retreated to $3376.0 in Q1 2026 per GCAN's latest filing, from $23806.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $23806.0 in Q4 2025 and bottomed at $3376.0 in Q1 2026.
• The 5-year median for Cost of Revenue is $11017.0 (2022), against an average of $11637.6.
• Across the five-year window, Cost of Revenue sank 87.6% in 2022 and soared 273.43% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $11017.0 in 2022, then increased by 15.98% to $12777.0 in 2023, then slumped by 50.11% to $6375.0 in 2024, then surged by 273.43% to $23806.0 in 2025, then tumbled by 85.82% to $3376.0 in 2026.
• Per Business Quant, the three latest GCAN Cost of Revenue figures stand at $3376.0 (Q1 2026), $23806.0 (Q4 2025), and $7412.0 (Q3 2025).